Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Hein

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Carcinogenesis|December 12, 2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerKristen S Purrington, Susan Slager, Diana Eccles, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic modelIsabelle Grootes, Renske Keeman, Fiona M Blows, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association ConsortiumSharon E Johnatty, Jonathan P Tyrer, Siddhartha Kar, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Human Genetics|April 15, 2016
Assessing the genetic architecture of epithelial ovarian cancer histological subtypesGabriel Cuellar-Partida, Yi Lu, Suzanne C Dixon, et al.
Cancer Immunology Research|April 26, 2014
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcomeBridget Charbonneau, Kirsten B Moysich, Kimberly R Kalli, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
International Journal of Epidemiology|September 6, 2016
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization studyJue-Sheng Ong, Gabriel Cuellar-Partida, Yi Lu, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Carcinogenesis|December 12, 2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerKristen S Purrington, Susan Slager, Diana Eccles, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic modelIsabelle Grootes, Renske Keeman, Fiona M Blows, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association ConsortiumSharon E Johnatty, Jonathan P Tyrer, Siddhartha Kar, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Human Genetics|April 15, 2016
Assessing the genetic architecture of epithelial ovarian cancer histological subtypesGabriel Cuellar-Partida, Yi Lu, Suzanne C Dixon, et al.
Cancer Immunology Research|April 26, 2014
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcomeBridget Charbonneau, Kirsten B Moysich, Kimberly R Kalli, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
International Journal of Epidemiology|September 6, 2016
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization studyJue-Sheng Ong, Gabriel Cuellar-Partida, Yi Lu, et al.
Pageof 17